Short answer
TREACE MEDICAL CONCEPTS, INC. (TMCI) filed an 8-K current report with the SEC on April 9, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure). Chief Commercial Officer Gaetano Guglielmino departing April 8, 2026, without reported dispute or disagreement.
TREACE MEDICAL CONCEPTS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Chief Commercial Officer Gaetano Guglielmino departing April 8, 2026, without reported dispute or disagreement
- Company eliminating the role; existing employees assume responsibilities and Senior Vice President, Sales reports to CEO John T. Treace
- Transition consulting through January 31, 2027, at $36,666.67 monthly plus COBRA premiums and other benefits
- Continued equity vesting, pro-rated 2026 target bonus, and apartment rent support increase transition-related obligations
- Release of claims and continuing confidentiality, nonsolicitation, and noncompetition obligations reduce legal and competitive-transition risk
Item 7.01 · Regulation FD Disclosure
- Management disclosed preliminary first-quarter 2026 revenue and cash balance results
- Updated full-year 2026 guidance signals revised expectations for revenue or financial performance
- Results and guidance remain preliminary and subject to material risks and uncertainties
- CFO Mark L. Hair signed the report dated April 9, 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other TREACE MEDICAL CONCEPTS, INC. 8-K filings
Get the next TMCI 8-K as it lands
Follow TMCI for push alerts, or ask the research agent what this filing means.